Identification of minimal residual disease using the clonesight test for ultrasensitive ctDNA detection to anticipate late relapse in early breast cancer

Identification of minimal residual disease using the clonesight test for ultrasensitive ctDNA detection to anticipate late relapse in early breast cancer

Abstract Background Early-stage breast cancer (BC) diagnosis significantly reduces mortality, yet relapse remains a concern due to undetectable minimal residual disease (MRD). Liquid biopsies offer real-time insights into tumor dynamics, aiding MRD detection and therapy response evaluation. However,...

Full description

Saved in:
Bibliographic Details
Main Authors: Iñaki Comino-Méndez, Jesús Velasco-Suelto, Javier Pascual, Esperanza López-López, Maria Elena Quirós-Ortega, Celia Gaona-Romero, Alejandro Martín-Muñoz, Patricia Losana, Yanira Heredia, Emilio Alba, Angel Guerrero-Zotano
Format: Article
Language:English
Published: BMC 2025-05-01
Series:Breast Cancer Research
Subjects:
Liquid biopsy
Early breast cancer
Circulating tumor DNA
Minimal residual disease
Online Access:https://doi.org/10.1186/s13058-025-02016-7
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://doi.org/10.1186/s13058-025-02016-7

Similar Items